Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Setting sights on the drugs of the future

29.03.2007
Researchers at The University of Nottingham have joined forces with one of the world’s leading pharmaceutical companies, AstraZeneca, to single out potential medicines of the future.

In a unique collaboration between academia and the pharmaceutical industry, teams of experts from both sides gathered together at an ‘ideas generation’ event, designed specifically to identify new areas for research into treatments that can be targeted at cancer, arthritis, cardio-pulmonary disease and other conditions.

The partnership underlines the significance of the EPSRC (Engineering and Physical Sciences Research Council)/AstraZeneca Doctoral Training Centre at the University, set up in 2006 as a direct collaboration with an industry partner to help develop pioneering treatments based on ‘targeted therapeutics’ — regarded as one of the significant future areas in 21st century medicine and in which The University of Nottingham is a UK leader.

The principle behind targeted therapeutics is to send medicines to the parts of the body where they are most needed, at the right time and in the right dose. In this way, diseased sites can be attacked directly, while healthy cells are bypassed, increasing the efficacy of the treatment and reducing side effects.

The University’s £2.5 million EPSRC/AstraZeneca Doctoral Training Centre is training 25 of the UK’s most promising pharmacy PhD students over the next five years in targeted therapeutics. Some of these PhD projects will now focus on ideas generated by the recent ‘ideas generation’ event with AstraZeneca. The ideas which came out of the day-and-a-half meeting, focused on a range of topics including chemistry of new drug delivery systems, biophysical analysis of dosage forms, process analytical technologies and cellular transport of drugs and drug carriers.

Dr Amanda Zeffman, Project Officer, said that the event was one of the first such meetings to take place between academics and scientists from industry.

Dr Zeffman said: “The intention was to generate ideas for PhD projects within the Doctoral Training Centre as well as to encourage general discussion in a relaxed environment, and it was extremely successful.

“By bringing together academics from the Schools of Chemistry, Maths, Computer Science and Physics, with PARD (Pharmaceutical and Analytical Research and Development) and discovery teams from AstraZeneca, we are able to combine the best of academia and industry to establish mutual interests and get a unique perspective on key areas in targeted therapeutics.”

EPSRC's first Doctoral Training Centres were launched in 2002 by EPSRC's Life Sciences Interface Programme. They offer a multi-disciplinary approach to postgraduate training bridging the gap between the medical, biological and physical sciences.

In the Nottingham Doctoral Training Centre, during the initial year of the four-year PhD, students will receive a thorough grounding in pharmaceutical sciences and will spend the first six months completing three, eight-week training projects, of which one is based within AstraZeneca. Each rotation will be in a different research group to enable students to benefit fully from the breadth of research being conducted in the School and by AstraZeneca.

The remaining three years of their time at the centre will be spent working on research projects centred on the theme of targeted therapeutics and drawing on everything from pharmaceutical nanotechnology and biopharmaceuticals to advanced physical, mathematical and life sciences.

AstraZeneca is a global leader in six major areas of healthcare — cardiovascular, gastrointestinal, infection, neuroscience, oncology and respiratory and inflammation — and the partnership with the company will provide a key commercial and clinical focus for the centre. It will improve the prospects of the students gaining jobs within the pharmaceutical industry after completing their training.

Emma Thorne | alfa
Further information:
http://www.nottingham.ac.uk/public-affairs/press-releases/index.phtml?menu=pressreleases&code=SETT-45/07&create_date=21-mar-2007

Further reports about: AstraZeneca Doctoral PhD Pharmaceutical Therapeutics targeted

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>